These days, most tuberculosis (TB) testing relies on sputum samples coughed up from the lungs, which makes sense since pulmonary TB is the most common form of the disease and sputum provides testable samples straight from the scene of infection. But scientists are saying there is a compelling case for the wider use of stool samples.
A drawback with sputum testing is that children and some people living with HIV find it difficult or impossible to cough up the sputum, writes Tiyese Jeranji in Spotlight. The resulting delays or uncertainties in diagnosis often have knock-on effects on treatment.
“Confirming TB in children is challenging as the disease is frequently paucibacillary (meaning the amount of TB in test samples is low and hard to detect),” says Dr Pedro da Silva, Operations Manager and Mycobacteriologist at Wits Diagnostic Innovation Hub and the National Priority Programme of the National Health Laboratory Service (NHLS).
“Children find it difficult to expectorate and when it is possible, the specimen volume may be suboptimal. To get a good respiratory specimen from children, more-invasive methods are frequently used, such as sputum induction. Often, skill sets to conduct the procedure or specialised equipment are unavailable. Caregivers may also refuse the invasive procedures.”
The race is thus on to find TB tests that do not rely on sputum.
Blood, urine, and saliva are all candidates, as, increasingly is stool. But while all have pros and cons and while the evidence base is still evolving, there seems to be a compelling case for the wider use of stool samples.
Already WHO recommended
Dr Anna Mandalakas, a paediatric specialist, chief of the Section on Global and Immigrant Health, and director of the Global Tuberculosis Programme of Texas Children’s Hospital, tells Spotlight that over the past decade, an increasing amount of research has been completed to study the use of stool samples for laboratory confirmation of TB. Their Baylor Global TB team recently demonstrated that, apart from just testing for TB, stool sample testing using gene sequencing technology can determine whether someone’s disease is drug-resistant. Such drug-susceptibility testing is becoming increasingly common.
The research is sufficiently advanced that, in 2021, the World Health Organisation (WHO) recommended the use of stool as a new sample type when diagnosing TB in children. In 2022, the WHO published guidelines on how to do these tests.
Petra de Haas, technical officer of laboratory services at the KNCV Tuberculosis Foundation, said at least three countries (Vietnam, Zambia and Ukraine) already use stool testing in their guidelines for routine testing; six countries are doing pilot implementations; and many others are preparing for the implementation of stool testing.
Stool-based TB diagnosis is not yet being implemented in South Africa. But, says Da Silva, the addition of stool as an additional specimen type for TB diagnosis in children here is under discussion and implementation is being planned, with possible introduction in 2023.
Why it works
While sputum samples have the advantage of coming straight from the lung, the TB bacteria present in stool samples have taken something of a detour.
“Many people with TB in their lungs swallow their sputum, which contains TB organisms,” explains Dr Gary Reubenson, a specialist in paediatric infectious diseases at the department of paediatrics and child care Empilweni Service and Research Unit at Rahima Moosa Mother and Child Hospital. “These don’t usually survive in our intestines, but their DNA can sometimes be detected in their stool. This could help us diagnose TB when we’re struggling using other methods.”
De Haas says that for years, “stool was considered a difficult sample for diagnosing bacterial diseases, as it contains a lot of other bacteria and organic material that interfere with diagnostic tests”. This, however, changed with the introduction of rapid molecular tests that can detect genetic material from the TB bacterium.
The good news is that the same molecular testing platform (GeneXpert) widely used in South Africa to test sputum samples for TB can also be used to test stool samples. But as Reubenson says, there are some differences in how samples are processed before testing.
Eligibility and sample collection
Da Silva says using stool as a diagnostic test for TB using the available molecular test is only recommended for children under 10.
“In other age groups, the current sputum and extra-pulmonary specimen types can be tested depending on signs and symptoms and presenting features of the disease. In people with advanced HIV infection where expectoration of sputum may be difficult, other tests can be performed, such as detection of lipoarabinomannan in urine specimens (using the point of care urine-LAM assay.”
The WHO’s practical manual for processing stool samples for diagnosis of childhood TB recommends stool collection should usually be done by the caregivers or patients themselves, depending on the child’s age. “Ideally, the collection takes place at the healthcare facility. However, to obtain a specimen on demand is often challenging, therefore, stool is collected at home and the patient or caregiver must return to the facility for specimen submission,” reads the manual.
Stool samples do not have any special storage requirements, adds Reubenson. “They are put into the same containers often used when collecting sputum and then taken to the Xpert machines, which are in lots of places in South Africa; many laboratories have them, but some clinics and hospitals too.
“The test concludes whether TB bacilli are present in the stool sample and quantifies the number of bacteria. It also reports if there are mutations in the DNA that lead to resistance to one of the first-line anti-TB drugs called rifampicin.”
It takes two hours to run the test, but since samples often have to be transported from health facilities to labs, the time from handing over a sample to getting a result can be longer.
Stool compared to other methods
“Current evidence suggests that the performance of GeneXpert is similar for sputum and stool specimens. There is a need for more evidence examining the performance of GeneXpert on specimens provided by different populations, particularly children and people living with HIV,” says Mandalakas.
Morten Ruhwald, director of the TB programme at the Foundation for Innovative Diagnostics (FIND), concurs that stool-based testing seems comparable to sputum-based testing, pointing out out that the two methods are complementary.
“The added value of this test is the fast diagnosis time and the more accessible sample. It addresses a major gap we have in childhood TB, which affects 1.1m children annually, of whom only 400 000 get notified and more than 200 000 die,” he says.
Thus far, it seems the sensitivity of stool testing is higher than that for tongue and urine samples, says De Haas. But she says more research is needed to investigate this.
According to systematic reviews cited in the WHO guideline for stool testing in kids, sensitivity using current molecular tests is in the region of 50% to 67%, and specificity around 98% to 99%. This indicates that, while false negatives are relatively common, false positives are rare. For comparison, sensitivity of sputum-based molecular TB tests in adults is well above 80% (although this applies only to people who can produce sputum).
Positive signs
Though not yet widely used, there are already some signs that stool testing is helping to boost TB diagnosis in children.
“The example of Zambia shows that implementation of stool testing for children substantially increases the number of TB patients notified and the proportion of notified TB patients with bacteriologically confirmed TB,” says De Haas, adding that in a pilot implementation study in the DRC, 15% of the children presumed to have TB tested positive for the disease.
“This is a high proportion. Previously, nearly all of these children would not have had access to a bacteriological test.” She adds that for a few of these children, the detected TB bacteria were shown to be resistant to the drug rifampicin, meaning effective treatment could be initiated immediately and mortality reduced.
Spotlight article – Testing stool can help detect TB in kids (Creative Commons Licence)
See more from MedicalBrief archives:
Advances in paediatric tuberculosis from 52nd Union World Conference on Lung Health
SA to expedite TB diagnosis/treatment as cases continue to soar
More than half of South Africans do not seek TB treatment – HSRC survey